SYNLOGIC, INC.
Close on Oct 19, 2026
- Market cap
- $13.29M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $0 | $-0.01 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $0.16 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | $10.00K | $-2.60 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | Before market open | $2.80M | $-1.71 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | $400.00K | $-2.57 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | Before market open | $35.00K | $-0.21 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | Before market open | $200.00K | $-0.23 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 29, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 11, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 12, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 17, 2022 | Before market open | – | – | – |
Press releases
Announcements Synlogic filed with the SEC
Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Synlogic Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Synlogic Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Synlogic Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Synlogic Adopts Limited Duration Stockholders Rights Plan
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Synlogic Announces Decision to Discontinue Synpheny-3 Study and
Results of operations · Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
Other events · EX-99.1 to Form 8-K
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Synlogic Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
Results of operations · EX-99 to Form 8-K
Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
Other events · EX-99.1 to Form 8-K
Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary
Other events · EX-99.1 to Form 8-K
ALL R LL RIIG GH HT TS R S RE ESE SER RV VE ED D..
Other events · EX-99.2 to Form 8-K
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Synlogic Announces Positive Top-Line Phase 2 Data
Other events · EX-99.1 to Form 8-K
Results Transforming Medicine Through Synthetic Biology October 18, 2022 Exhibit 99.2
Other events · EX-99.2 to Form 8-K
Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Biology Q4 and Full Year 2021 Financial Results & Business Update March 17, 2022 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Synlogic Reports Third Quarter Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bringing the Transformative Power of
Results of operations · EX-99.2 to Form 8-K
Synlogic and Ginkgo Bioworks Announce Investigational
Other events · EX-99.1 to Form 8-K